CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Biomarin Pharmaceutical Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Biomarin Pharmaceutical Inc
770 Lindaro Street
Phone: (415) 506-6700p:415 506-6700 SAN RAFAEL, CA  94901  United States Ticker: BMRNBMRN
Business Summary
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202512/31/2024YesYes--Yes

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
5122 Drugs, drug proprietaries, and druggists' sundries
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board Richard A.Meier 65 12/1/2023 12/14/2006
President, Chief Executive Officer, Director AlexanderHardy 56 12/1/2023 12/1/2023
Chief Financial Officer, Executive Vice President Brian R.Mueller 51 1/1/2024 3/1/2011
16 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
BIOMARIN (U.K.) LTD. 10 BLOOMSBURY WAY LONDON UK
BIOMARIN EUROPE LIMITED 6TH FLOOR 2 GRAND CANAL SQUARE DUBLIN 2 IE
BIOMARIN COMMERCIAL LIMITED 6TH FLOOR 2 GRAND CANAL SQUARE DUBLIN 2DUBLIN IE
6 additional Subsidiary records available in full report.

Business Names
Business Name
BIOMARIN (U.K.) LTD.
BioMarin Commercial Ltd
BioMarin Deutschland GmbH
8 additional Business Names available in full report.

General Information
Number of Employees: 3,040 (As of 12/31/2024)
Outstanding Shares: 191,775,665 (As of 4/25/2025)
Shareholders: 34
Stock Exchange: NASD
Federal Tax Id: 680397820
Fax Number: (302) 636-5454
Email Address: CorporateCommunications2@bmrn.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, July 7, 2025